Aclaris Therapeutics (ACRS) Non-Current Deffered Revenue (2014 - 2026)

Aclaris Therapeutics' Non-Current Deffered Revenue history runs 5 years deep, the most recent figure standing at $15.3 million for Q1 2026.

• In Q1 2026, Non-Current Deffered Revenue fell 20.42% year-over-year to $15.3 million; the TTM figure through Mar 2026 stood at $15.3 million (down 20.42% YoY), while the FY2025 annual figure was $16.2 million, down 19.31% from the prior year.
• Non-Current Deffered Revenue was $15.3 million for Q1 2026 at Aclaris Therapeutics, down from $16.2 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $21.2 million in Q3 2024 to a low of $15.3 million in Q1 2026.
• Historically, Non-Current Deffered Revenue has averaged $18.2 million across 3 years, with a median of $18.2 million in 2025.
• The sharpest annual moves came in 2025 and 2026: Non-Current Deffered Revenue dropped 17.42% in 2025, then slipped 20.42% in 2026.
• A 3-year view of Non-Current Deffered Revenue shows it stood at $20.0 million in 2024, then fell by 19.31% to $16.2 million in 2025, then slipped by 5.46% to $15.3 million in 2026.
• The last three Non-Current Deffered Revenue figures came in at $15.3 million (Q1 2026), $16.2 million (Q4 2025), and $17.5 million (Q3 2025), per Business Quant data.